Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1573 Views
-
Last post by Tif
-
- 1 Replies
- 214 Views
-
Last post by Leonard
-
- 2 Replies
- 780 Views
-
Last post by DIM
-
- 0 Replies
- 1257 Views
-
Last post by Tif
-
- 0 Replies
- 1779 Views
-
Last post by Tif
-
- 0 Replies
- 1351 Views
-
Last post by Tif
-
- 1 Replies
- 1074 Views
-
Last post by 1eye
-
- 4 Replies
- 2217 Views
-
Last post by NHE
-
- 1 Replies
- 1473 Views
-
Last post by tzootsi